Prothena Corp Analyst Ratings
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $62
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)
RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $24
Prothena Corp Analyst Ratings
RBC Cuts Price Target on Prothena to $24 From $28, Keeps Sector Perform, Speculative Risk
Prothena's Promising Pipeline and Strong Financials Merit a Buy Rating, With an $83 Price Target
Prothena Corp Analyst Ratings
Buy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic Partnerships
Prothena (PRTA) Receives a Buy From Piper Sandler
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX), Bioxcel Therapeutics (BTAI) and Prothena (PRTA)
Buy Rating Affirmed for Prothena Amid Strong Pipeline and Financial Health
Prothena Corp Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA)
Prothena Corp Analyst Ratings
Prothena Corp Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
Oppenheimer Cuts Prothena Price Target to $80 From $98, Maintains Outperform Rating
Buy Rating Affirmed on Prothena Amid Strong Pipeline Progress and Solid Financials